We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$47.1B
AUM Growth
+$2.61B
(+5.9%)
Cap. Flow
-$501M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
14.43%
Holding
3,576
New
705
Increased
706
Reduced
825
Closed
988
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$417M |
| 2 |
Meta Platforms (Facebook)
META
|
+$383M |
| 3 |
Amazon
AMZN
|
+$308M |
| 4 |
Microsoft
MSFT
|
+$293M |
| 5 |
GE Aerospace
GE
|
+$263M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$312M |
| 2 |
Bank of America
BAC
|
+$292M |
| 3 |
ExxonMobil
XOM
|
+$274M |
| 4 |
lululemon athletica
LULU
|
+$238M |
| 5 |
Qualcomm
QCOM
|
+$228M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.05% |
| 2 | Technology | 14.35% |
| 3 | Consumer Discretionary | 13.97% |
| 4 | Financials | 9.9% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
TransUnion
TRU
$14.8B
| $41.4M | 0.09% |
666,108
-678,736
| -50% | -$44.4M |
|
|
AKRO
252
DELISTED
Akero Therapeutics
AKRO
| $41.4M | 0.09% |
1,081,725
-421,639
| -28% | -$18.8M |
|
253
Avient
AVNT
$3.45B
| $41.1M | 0.09% |
999,615
+60,866
| +6% | +$2.43M |
|
254
PBF Energy
PBF
$7.29B
| $41M | 0.09% |
946,724
+742,855
| +364% | +$31.3M |
|
255
VF Corp
VFC
$6.68B
| $40.8M | 0.09% |
1,782,103
+1,183,917
| +198% | +$31.1M |
|
256
Sun Communities
SUI
$15B
| $40.8M | 0.09% |
289,617
+275,894
| +2,010% | +$40.3M |
|
257
Advanced Micro Devices
AMD
$851B
| $40.8M | 0.09% |
416,171
-932,361
| -69% | -$75.9M |
|
258
Ecopetrol
EC
$32.9B
| $40.2M | 0.09% |
3,806,160
+573,319
| +18% | +$6.22M |
|
259
T. Rowe Price
TROW
$25B
| $39.5M | 0.08% |
350,222
+88,809
| +34% | +$10.1M |
|
260
Wendy's
WEN
$1.33B
| $39.4M | 0.08% |
1,811,205
+708,312
| +64% | +$15.6M |
|
261
Hims & Hers Health
HIMS
$6.5B
| $39.4M | 0.08% |
3,970,937
-516,101
| -12% | -$4.52M |
|
262
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$34.7B
| $39.4M | 0.08% |
+359,287
| New | +$38.9M |
|
263
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
| $39.2M | 0.08% |
368,451
+169,900
| +86% | +$17.8M |
|
264
Performance Food Group
PFGC
$17.5B
| $39.2M | 0.08% |
649,040
-100,792
| -13% | -$5.89M |
|
265
MGM Resorts International
MGM
$11.7B
| $39.1M | 0.08% |
881,171
-1,195,887
| -58% | -$49.7M |
|
266
Bilibili
BILI
$7.18B
| $39M | 0.08% |
1,659,574
-5,928,528
| -78% | -$141M |
|
267
CALL
Nike
NKE
$61.9B
| $38.9M | 0.08% |
+316,800
| New | +$38.9M |
|
|
268
Cigna
CI
$76.6B
| $38.5M | 0.08% |
150,860
-1,072,019
| -88% | -$312M |
|
269
Freeport-McMoran
FCX
$90B
| $38.3M | 0.08% |
935,324
+399,853
| +75% | +$16.6M |
|
270
Air Products & Chemicals
APD
$66.3B
| $38.2M | 0.08% |
133,023
-10,598
| -7% | -$3.09M |
|
271
PUT
Palo Alto Networks
PANW
$264B
| $38M | 0.08% |
380,400
+101,600
| +36% | +$8.61M |
|
272
CALL
iShares China Large-Cap ETF
FXI
$4.31B
| $37.9M | 0.08% |
1,282,900
+837,700
| +188% | +$25.2M |
|
273
TSMC
TSM
$2.09T
| $37.9M | 0.08% |
407,079
+274,367
| +207% | +$24.6M |
|
274
Tenet Healthcare
THC
$20.1B
| $37.8M | 0.08% |
635,328
+443,715
| +232% | +$24.7M |
|
|
RETA
275
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $37.7M | 0.08% |
414,954
+209,612
| +102% | +$12.3M |
|
Similar funds
Marshall Wace's Q1 2023 Portfolio in Review
As of Q1 2023, Marshall Wace held 3,576 positions worth $47.1B, up 5.9% from $44.5B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Marshall Wace's Q1 2023 filing shows 705 new, 706 increased, 825 reduced and 988 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 541,764 shares worth $131M. The largest sale was Cigna, an estimated $312M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- Marshall Wace's largest Q1 2023 buy was Madrigal Pharmaceuticals: 541,764 shares worth $131M.
- Marshall Wace added most to Walmart Inc in Q1 2023, an estimated $417M increase.
- Marshall Wace's biggest Q1 2023 reduction was Cigna, cutting an estimated $312M.
- Marshall Wace fully exited Merck in Q1 2023, selling an estimated $115M.
- Marshall Wace's ten largest holdings make up 14% of its $47.1B portfolio in Q1 2023.
- Marshall Wace opened 705 new positions and closed 988 in Q1 2023.
- Marshall Wace's portfolio value rose 5.9% quarter-over-quarter to $47.1B.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.